Abstract
Our data reveal valuable palliation with preservation of KPS and an option for steroid withdrawal in patients treated with BEV, supporting the role of this therapy in late-stage disease.
Hofer, S; Elandt, K; Greil, R; Hottinger, A F; Huber, U; Lemke, D; Marosi, C; Ochsenbein, A; Pichler, J; Roelcke, U; Weder, P; Zander, T; Wick, W; Weller, M (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncologica, 50(5):630-635.
Abstract
Our data reveal valuable palliation with preservation of KPS and an option for steroid withdrawal in patients treated with BEV, supporting the role of this therapy in late-stage disease.
Statistics
Citations
Dimensions.ai Metrics
Altmetrics
Downloads
Additional indexing
| Item Type: | Journal Article, refereed, original work |
|---|---|
| Communities & Collections: | 04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology |
| Dewey Decimal Classification: | 610 Medicine & health |
| Scopus Subject Areas: | Health Sciences > Hematology
Health Sciences > Oncology Health Sciences > Radiology, Nuclear Medicine and Imaging |
| Language: | English |
| Date: | 2011 |
| Deposited On: | 14 Nov 2011 13:37 |
| Last Modified: | 23 Jan 2022 19:25 |
| Publisher: | Taylor & Francis |
| ISSN: | 0284-186X |
| OA Status: | Closed |
| Publisher DOI: | https://doi.org/10.3109/0284186X.2011.572913 |
| PubMed ID: | 21495907 |
Hofer, S